RNS Number : 6711N
N4 Pharma PLC
21 May 2020

21 May 2020

N4 Pharma plc
("**N4 Pharma**" or the "**Company**")

Holding in Company

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has been notified that Mr David Farrier's beneficial interest in the Company's share capital remains at 12,175,510 ordinary shares in the Company, representing 8.00 per cent. of the Company's issued share capital. Mr Farrier's holding was diluted through a notifiable threshold as a result of the issue of new ordinary shares in the Company pursuant to the placing announced on 13 May 2020.

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR
Allenby Capital Limited — Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Turner Pope Investments (TPI) Ltd — Tel: +44(0)20 3657 0050
Andrew Thacker
Scott PR — Tel: +44(0)1477 539 539
Georgia Smith

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments,

milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

HOLFLFFEESILFII